Literature DB >> 23319065

[Retinal vein occlusion. Diagnosis or symptom?].

J Matlach1, W Göbel.   

Abstract

Behçet's disease is a chronic recurrent systemic vasculitis and can affect nearly all organ systems. Eye involvement is characterized by uveitis with occlusive retinal vasculitis. Oral aphthous ulcers are the major primary symptom and arthritis, genital ulcerations and skin lesions are common extraocular manifestations. Gastrointestinal and vascular symptoms or manifestations of the central nervous system are less frequently seen. Biologic agents are used alone or in combination with immunosuppressive or cytotoxic drugs to prevent relapse as the prognosis is poor in patients with retinal vasculitis.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23319065     DOI: 10.1007/s00347-012-2764-z

Source DB:  PubMed          Journal:  Ophthalmologe        ISSN: 0941-293X            Impact factor:   1.059


  10 in total

1.  Multicenter study of infliximab for refractory uveoretinitis in Behçet disease.

Authors:  Annabelle A Okada; Hiroshi Goto; Shigeaki Ohno; Manabu Mochizuki
Journal:  Arch Ophthalmol       Date:  2012-05

2.  Intravitreal infliximab for sight-threatening relapsing uveitis in Behçet disease: a pilot study in 15 patients.

Authors:  Nikos Markomichelakis; Evie Delicha; Stylianos Masselos; Petros P Sfikakis
Journal:  Am J Ophthalmol       Date:  2012-07-11       Impact factor: 5.258

3.  EULAR recommendations for the management of Behçet disease.

Authors:  G Hatemi; A Silman; D Bang; B Bodaghi; A M Chamberlain; A Gul; M H Houman; I Kötter; I Olivieri; C Salvarani; P P Sfikakis; A Siva; M R Stanford; N Stübiger; S Yurdakul; H Yazici
Journal:  Ann Rheum Dis       Date:  2008-01-31       Impact factor: 19.103

Review 4.  Behcet's disease: from East to West.

Authors:  Fereydoun Davatchi; Farhad Shahram; Cheyda Chams-Davatchi; Hormoz Shams; Abdolhadi Nadji; Massoomeh Akhlaghi; Tahereh Faezi; Zahra Ghodsi; Alireza Faridar; Farima Ashofteh; Bahar Sadeghi Abdollahi
Journal:  Clin Rheumatol       Date:  2010-03-31       Impact factor: 2.980

Review 5.  Criteria for diagnosis of Behçet's disease. International Study Group for Behçet's Disease.

Authors: 
Journal:  Lancet       Date:  1990-05-05       Impact factor: 79.321

6.  Effect of infliximab on sight-threatening panuveitis in Behçet's disease.

Authors:  P P Sfikakis; P G Theodossiadis; C G Katsiari; P Kaklamanis; N N Markomichelakis
Journal:  Lancet       Date:  2001-07-28       Impact factor: 79.321

7.  Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Behçet's disease: an open-label trial.

Authors:  Ilknur Tugal-Tutkun; Abdulbaki Mudun; Meri Urgancioglu; Sevil Kamali; Esen Kasapoglu; Murat Inanc; Ahmet Gül
Journal:  Arthritis Rheum       Date:  2005-08

8.  Long-term remission after cessation of interferon-α treatment in patients with severe uveitis due to Behçet's disease.

Authors:  Christoph M E Deuter; Manfred Zierhut; Antje Möhle; Reinhard Vonthein; Nicole Stöbiger; Ina Kötter
Journal:  Arthritis Rheum       Date:  2010-09

9.  [Epidemiology and clinical aspects of Adamantiades-Behçet disease in Gemany. Current data].

Authors:  A Altenburg; A Mahr; C Maldini; C E Kneifel; L Krause; I Kötter; T Stache; N G Bonitsis; C C Zouboulis
Journal:  Ophthalmologe       Date:  2012-06       Impact factor: 1.059

Review 10.  Ocular Behçet disease: current therapeutic approaches.

Authors:  Cem Evereklioglu
Journal:  Curr Opin Ophthalmol       Date:  2011-11       Impact factor: 3.761

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.